LSP5-2157 a new inhibitor of vesicular glutamate transporters

Vesicular glutamate transporters (VGLUT1-3) mediate the uptake of glutamate into synaptic vesicles. VGLUTs are pivotal actors of excitatory transmission and of almost all brain functions. Their implication in various pathologies has been clearly documented. Despite their functional importance, the p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2020-03, Vol.164, p.107902-107902, Article 107902
Hauptverfasser: Poirel, Odile, Mamer, Lauren E., Herman, Melissa A., Arnulf-Kempcke, Marie, Kervern, Myriam, Potier, Brigitte, Miot, Stephanie, Wang, Jing, Favre-Besse, Franck-Cyril, Brabet, Isabelle, Laras, Younès, Bertrand, Hugues-Olivier, Acher, Francine, Pin, Jean-Philippe, Puel, Jean-Luc, Giros, Bruno, Epelbaum, Jacques, Rosenmund, Christian, Dutar, Patrick, Daumas, Stephanie, El Mestikawy, Salah, Pietrancosta, Nicolas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 107902
container_issue
container_start_page 107902
container_title Neuropharmacology
container_volume 164
creator Poirel, Odile
Mamer, Lauren E.
Herman, Melissa A.
Arnulf-Kempcke, Marie
Kervern, Myriam
Potier, Brigitte
Miot, Stephanie
Wang, Jing
Favre-Besse, Franck-Cyril
Brabet, Isabelle
Laras, Younès
Bertrand, Hugues-Olivier
Acher, Francine
Pin, Jean-Philippe
Puel, Jean-Luc
Giros, Bruno
Epelbaum, Jacques
Rosenmund, Christian
Dutar, Patrick
Daumas, Stephanie
El Mestikawy, Salah
Pietrancosta, Nicolas
description Vesicular glutamate transporters (VGLUT1-3) mediate the uptake of glutamate into synaptic vesicles. VGLUTs are pivotal actors of excitatory transmission and of almost all brain functions. Their implication in various pathologies has been clearly documented. Despite their functional importance, the pharmacology of VGLUTs is limited to a few dyes such as Trypan Blue, Rose Bengal or Brilliant Yellow type. Here, we report the design and evaluation of new potent analogs based on Trypan Blue scaffold. Our best compound, named LSP5-2157, has an EC50 of 50 nM on glutamate vesicular uptake. Using a 3D homology model of VGLUT1 and docking experiments, we determined its putative binding subdomains within vesicular glutamate transporters and validated the structural requirement for VGLUT inhibition. To better estimate the specificity and potency of LSP5-2157, we also investigated its ability to block glutamatergic transmission in autaptic hippocampal cells. Neither glutamate receptors nor GABAergic transmission or transmission machinery were affected by LSP5-2157. Low doses of compound reversibly reduce glutamatergic neurotransmission in hippocampal autpases. LSP5-2157 had a low and depressing effect on synaptic efficacy in hippocampal slice. Furthermore, LSP5-2157 had no effect on NMDA-R- mediated fEPSP but reduce synaptic plasticity induced by 3 trains of 100 Hz. Finally, LSP5-2157 had the capacity to inhibit VGLUT3-dependent auditory synaptic transmission in the guinea pig cochlea. In this model, it abolished the compound action potential of auditory nerve at high concentration showing the limited permeation of LSP5-2157 in an in-vivo model. In summary, the new ligand LSP5-2157, has a high affinity and specificity for VGLUTs and shows some permeability in isolated neuron, tissue preparations or in vivo in the auditory system. These findings broaden the field of VGLUTs inhibitors and open the way to their use to assess glutamatergic functions in vitro and in vivo.
doi_str_mv 10.1016/j.neuropharm.2019.107902
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03043497v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390819304733</els_id><sourcerecordid>2322742540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-a77117b32153fd6cea3e4a2f04b4a3b04357456e2fbf6a9cd3edd94f81b48e1d3</originalsourceid><addsrcrecordid>eNqFkE1Lw0AURQdRbK3-BclSF6nzlcxk4aIWtUJBQV0Pk8mLnZJk6kxS8d-bklqXrh48zr0XDkIRwVOCSXqznjbQebdZaV9PKSZZ_xYZpkdoTKRgscApP0ZjjKmMWYblCJ2FsMYYc0nkKRoxIskOHKPb5etLElOSiEhHDXxFtlnZ3LbOR66MthCs6Srto4-qa3WtW4har5uwcb4FH87RSamrABf7O0HvD_dv80W8fH58ms-WseGJbGMtBCEiZ_0MK4vUgGbANS0xz7lmOeYsETxJgZZ5merMFAyKIuOlJDmXQAo2QddD70pXauNtrf23ctqqxWypdj_M-hKeiS3p2auB3Xj32UFoVW2DgarSDbguKMooFZwmHPeoHFDjXQgeykM3wWonWq3Vn2i1E60G0X30cr_S5TUUh-Cv2R64GwDovWwteBWMhcZAYT2YVhXO_r_yA-3Bkmc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322742540</pqid></control><display><type>article</type><title>LSP5-2157 a new inhibitor of vesicular glutamate transporters</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Poirel, Odile ; Mamer, Lauren E. ; Herman, Melissa A. ; Arnulf-Kempcke, Marie ; Kervern, Myriam ; Potier, Brigitte ; Miot, Stephanie ; Wang, Jing ; Favre-Besse, Franck-Cyril ; Brabet, Isabelle ; Laras, Younès ; Bertrand, Hugues-Olivier ; Acher, Francine ; Pin, Jean-Philippe ; Puel, Jean-Luc ; Giros, Bruno ; Epelbaum, Jacques ; Rosenmund, Christian ; Dutar, Patrick ; Daumas, Stephanie ; El Mestikawy, Salah ; Pietrancosta, Nicolas</creator><creatorcontrib>Poirel, Odile ; Mamer, Lauren E. ; Herman, Melissa A. ; Arnulf-Kempcke, Marie ; Kervern, Myriam ; Potier, Brigitte ; Miot, Stephanie ; Wang, Jing ; Favre-Besse, Franck-Cyril ; Brabet, Isabelle ; Laras, Younès ; Bertrand, Hugues-Olivier ; Acher, Francine ; Pin, Jean-Philippe ; Puel, Jean-Luc ; Giros, Bruno ; Epelbaum, Jacques ; Rosenmund, Christian ; Dutar, Patrick ; Daumas, Stephanie ; El Mestikawy, Salah ; Pietrancosta, Nicolas</creatorcontrib><description>Vesicular glutamate transporters (VGLUT1-3) mediate the uptake of glutamate into synaptic vesicles. VGLUTs are pivotal actors of excitatory transmission and of almost all brain functions. Their implication in various pathologies has been clearly documented. Despite their functional importance, the pharmacology of VGLUTs is limited to a few dyes such as Trypan Blue, Rose Bengal or Brilliant Yellow type. Here, we report the design and evaluation of new potent analogs based on Trypan Blue scaffold. Our best compound, named LSP5-2157, has an EC50 of 50 nM on glutamate vesicular uptake. Using a 3D homology model of VGLUT1 and docking experiments, we determined its putative binding subdomains within vesicular glutamate transporters and validated the structural requirement for VGLUT inhibition. To better estimate the specificity and potency of LSP5-2157, we also investigated its ability to block glutamatergic transmission in autaptic hippocampal cells. Neither glutamate receptors nor GABAergic transmission or transmission machinery were affected by LSP5-2157. Low doses of compound reversibly reduce glutamatergic neurotransmission in hippocampal autpases. LSP5-2157 had a low and depressing effect on synaptic efficacy in hippocampal slice. Furthermore, LSP5-2157 had no effect on NMDA-R- mediated fEPSP but reduce synaptic plasticity induced by 3 trains of 100 Hz. Finally, LSP5-2157 had the capacity to inhibit VGLUT3-dependent auditory synaptic transmission in the guinea pig cochlea. In this model, it abolished the compound action potential of auditory nerve at high concentration showing the limited permeation of LSP5-2157 in an in-vivo model. In summary, the new ligand LSP5-2157, has a high affinity and specificity for VGLUTs and shows some permeability in isolated neuron, tissue preparations or in vivo in the auditory system. These findings broaden the field of VGLUTs inhibitors and open the way to their use to assess glutamatergic functions in vitro and in vivo.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2019.107902</identifier><identifier>PMID: 31811873</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Action Potentials - drug effects ; Animals ; Cochlea - drug effects ; Cochlear Nerve - drug effects ; Excitatory Postsynaptic Potentials - drug effects ; Glutamatergic transmission modulation ; Guinea Pigs ; Hippocampus - cytology ; Hippocampus - drug effects ; Life Sciences ; Mice ; Mice, Inbred C57BL ; Models, Molecular ; Neurobiology ; Neurons - drug effects ; Neurons and Cognition ; Neuropharmacology ; Synapses - drug effects ; Synaptic Transmission - drug effects ; Vesicular Glutamate Transport Proteins - antagonists &amp; inhibitors ; Vesicular Glutamate Transport Proteins - metabolism ; Vesicular glutamate transporters (VGLUTs)</subject><ispartof>Neuropharmacology, 2020-03, Vol.164, p.107902-107902, Article 107902</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-a77117b32153fd6cea3e4a2f04b4a3b04357456e2fbf6a9cd3edd94f81b48e1d3</citedby><cites>FETCH-LOGICAL-c458t-a77117b32153fd6cea3e4a2f04b4a3b04357456e2fbf6a9cd3edd94f81b48e1d3</cites><orcidid>0000-0001-5876-9822 ; 0000-0002-9934-7818 ; 0000-0002-6253-0002 ; 0000-0002-8170-1196 ; 0000-0002-7234-9987 ; 0000-0002-5413-4181 ; 0000-0002-9235-7298 ; 0000-0001-7048-7617 ; 0000-0002-1423-345X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0028390819304733$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31811873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03043497$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Poirel, Odile</creatorcontrib><creatorcontrib>Mamer, Lauren E.</creatorcontrib><creatorcontrib>Herman, Melissa A.</creatorcontrib><creatorcontrib>Arnulf-Kempcke, Marie</creatorcontrib><creatorcontrib>Kervern, Myriam</creatorcontrib><creatorcontrib>Potier, Brigitte</creatorcontrib><creatorcontrib>Miot, Stephanie</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Favre-Besse, Franck-Cyril</creatorcontrib><creatorcontrib>Brabet, Isabelle</creatorcontrib><creatorcontrib>Laras, Younès</creatorcontrib><creatorcontrib>Bertrand, Hugues-Olivier</creatorcontrib><creatorcontrib>Acher, Francine</creatorcontrib><creatorcontrib>Pin, Jean-Philippe</creatorcontrib><creatorcontrib>Puel, Jean-Luc</creatorcontrib><creatorcontrib>Giros, Bruno</creatorcontrib><creatorcontrib>Epelbaum, Jacques</creatorcontrib><creatorcontrib>Rosenmund, Christian</creatorcontrib><creatorcontrib>Dutar, Patrick</creatorcontrib><creatorcontrib>Daumas, Stephanie</creatorcontrib><creatorcontrib>El Mestikawy, Salah</creatorcontrib><creatorcontrib>Pietrancosta, Nicolas</creatorcontrib><title>LSP5-2157 a new inhibitor of vesicular glutamate transporters</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Vesicular glutamate transporters (VGLUT1-3) mediate the uptake of glutamate into synaptic vesicles. VGLUTs are pivotal actors of excitatory transmission and of almost all brain functions. Their implication in various pathologies has been clearly documented. Despite their functional importance, the pharmacology of VGLUTs is limited to a few dyes such as Trypan Blue, Rose Bengal or Brilliant Yellow type. Here, we report the design and evaluation of new potent analogs based on Trypan Blue scaffold. Our best compound, named LSP5-2157, has an EC50 of 50 nM on glutamate vesicular uptake. Using a 3D homology model of VGLUT1 and docking experiments, we determined its putative binding subdomains within vesicular glutamate transporters and validated the structural requirement for VGLUT inhibition. To better estimate the specificity and potency of LSP5-2157, we also investigated its ability to block glutamatergic transmission in autaptic hippocampal cells. Neither glutamate receptors nor GABAergic transmission or transmission machinery were affected by LSP5-2157. Low doses of compound reversibly reduce glutamatergic neurotransmission in hippocampal autpases. LSP5-2157 had a low and depressing effect on synaptic efficacy in hippocampal slice. Furthermore, LSP5-2157 had no effect on NMDA-R- mediated fEPSP but reduce synaptic plasticity induced by 3 trains of 100 Hz. Finally, LSP5-2157 had the capacity to inhibit VGLUT3-dependent auditory synaptic transmission in the guinea pig cochlea. In this model, it abolished the compound action potential of auditory nerve at high concentration showing the limited permeation of LSP5-2157 in an in-vivo model. In summary, the new ligand LSP5-2157, has a high affinity and specificity for VGLUTs and shows some permeability in isolated neuron, tissue preparations or in vivo in the auditory system. These findings broaden the field of VGLUTs inhibitors and open the way to their use to assess glutamatergic functions in vitro and in vivo.</description><subject>Action Potentials - drug effects</subject><subject>Animals</subject><subject>Cochlea - drug effects</subject><subject>Cochlear Nerve - drug effects</subject><subject>Excitatory Postsynaptic Potentials - drug effects</subject><subject>Glutamatergic transmission modulation</subject><subject>Guinea Pigs</subject><subject>Hippocampus - cytology</subject><subject>Hippocampus - drug effects</subject><subject>Life Sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Models, Molecular</subject><subject>Neurobiology</subject><subject>Neurons - drug effects</subject><subject>Neurons and Cognition</subject><subject>Neuropharmacology</subject><subject>Synapses - drug effects</subject><subject>Synaptic Transmission - drug effects</subject><subject>Vesicular Glutamate Transport Proteins - antagonists &amp; inhibitors</subject><subject>Vesicular Glutamate Transport Proteins - metabolism</subject><subject>Vesicular glutamate transporters (VGLUTs)</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AURQdRbK3-BclSF6nzlcxk4aIWtUJBQV0Pk8mLnZJk6kxS8d-bklqXrh48zr0XDkIRwVOCSXqznjbQebdZaV9PKSZZ_xYZpkdoTKRgscApP0ZjjKmMWYblCJ2FsMYYc0nkKRoxIskOHKPb5etLElOSiEhHDXxFtlnZ3LbOR66MthCs6Srto4-qa3WtW4har5uwcb4FH87RSamrABf7O0HvD_dv80W8fH58ms-WseGJbGMtBCEiZ_0MK4vUgGbANS0xz7lmOeYsETxJgZZ5merMFAyKIuOlJDmXQAo2QddD70pXauNtrf23ctqqxWypdj_M-hKeiS3p2auB3Xj32UFoVW2DgarSDbguKMooFZwmHPeoHFDjXQgeykM3wWonWq3Vn2i1E60G0X30cr_S5TUUh-Cv2R64GwDovWwteBWMhcZAYT2YVhXO_r_yA-3Bkmc</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Poirel, Odile</creator><creator>Mamer, Lauren E.</creator><creator>Herman, Melissa A.</creator><creator>Arnulf-Kempcke, Marie</creator><creator>Kervern, Myriam</creator><creator>Potier, Brigitte</creator><creator>Miot, Stephanie</creator><creator>Wang, Jing</creator><creator>Favre-Besse, Franck-Cyril</creator><creator>Brabet, Isabelle</creator><creator>Laras, Younès</creator><creator>Bertrand, Hugues-Olivier</creator><creator>Acher, Francine</creator><creator>Pin, Jean-Philippe</creator><creator>Puel, Jean-Luc</creator><creator>Giros, Bruno</creator><creator>Epelbaum, Jacques</creator><creator>Rosenmund, Christian</creator><creator>Dutar, Patrick</creator><creator>Daumas, Stephanie</creator><creator>El Mestikawy, Salah</creator><creator>Pietrancosta, Nicolas</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-5876-9822</orcidid><orcidid>https://orcid.org/0000-0002-9934-7818</orcidid><orcidid>https://orcid.org/0000-0002-6253-0002</orcidid><orcidid>https://orcid.org/0000-0002-8170-1196</orcidid><orcidid>https://orcid.org/0000-0002-7234-9987</orcidid><orcidid>https://orcid.org/0000-0002-5413-4181</orcidid><orcidid>https://orcid.org/0000-0002-9235-7298</orcidid><orcidid>https://orcid.org/0000-0001-7048-7617</orcidid><orcidid>https://orcid.org/0000-0002-1423-345X</orcidid></search><sort><creationdate>20200301</creationdate><title>LSP5-2157 a new inhibitor of vesicular glutamate transporters</title><author>Poirel, Odile ; Mamer, Lauren E. ; Herman, Melissa A. ; Arnulf-Kempcke, Marie ; Kervern, Myriam ; Potier, Brigitte ; Miot, Stephanie ; Wang, Jing ; Favre-Besse, Franck-Cyril ; Brabet, Isabelle ; Laras, Younès ; Bertrand, Hugues-Olivier ; Acher, Francine ; Pin, Jean-Philippe ; Puel, Jean-Luc ; Giros, Bruno ; Epelbaum, Jacques ; Rosenmund, Christian ; Dutar, Patrick ; Daumas, Stephanie ; El Mestikawy, Salah ; Pietrancosta, Nicolas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-a77117b32153fd6cea3e4a2f04b4a3b04357456e2fbf6a9cd3edd94f81b48e1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Action Potentials - drug effects</topic><topic>Animals</topic><topic>Cochlea - drug effects</topic><topic>Cochlear Nerve - drug effects</topic><topic>Excitatory Postsynaptic Potentials - drug effects</topic><topic>Glutamatergic transmission modulation</topic><topic>Guinea Pigs</topic><topic>Hippocampus - cytology</topic><topic>Hippocampus - drug effects</topic><topic>Life Sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Models, Molecular</topic><topic>Neurobiology</topic><topic>Neurons - drug effects</topic><topic>Neurons and Cognition</topic><topic>Neuropharmacology</topic><topic>Synapses - drug effects</topic><topic>Synaptic Transmission - drug effects</topic><topic>Vesicular Glutamate Transport Proteins - antagonists &amp; inhibitors</topic><topic>Vesicular Glutamate Transport Proteins - metabolism</topic><topic>Vesicular glutamate transporters (VGLUTs)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poirel, Odile</creatorcontrib><creatorcontrib>Mamer, Lauren E.</creatorcontrib><creatorcontrib>Herman, Melissa A.</creatorcontrib><creatorcontrib>Arnulf-Kempcke, Marie</creatorcontrib><creatorcontrib>Kervern, Myriam</creatorcontrib><creatorcontrib>Potier, Brigitte</creatorcontrib><creatorcontrib>Miot, Stephanie</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Favre-Besse, Franck-Cyril</creatorcontrib><creatorcontrib>Brabet, Isabelle</creatorcontrib><creatorcontrib>Laras, Younès</creatorcontrib><creatorcontrib>Bertrand, Hugues-Olivier</creatorcontrib><creatorcontrib>Acher, Francine</creatorcontrib><creatorcontrib>Pin, Jean-Philippe</creatorcontrib><creatorcontrib>Puel, Jean-Luc</creatorcontrib><creatorcontrib>Giros, Bruno</creatorcontrib><creatorcontrib>Epelbaum, Jacques</creatorcontrib><creatorcontrib>Rosenmund, Christian</creatorcontrib><creatorcontrib>Dutar, Patrick</creatorcontrib><creatorcontrib>Daumas, Stephanie</creatorcontrib><creatorcontrib>El Mestikawy, Salah</creatorcontrib><creatorcontrib>Pietrancosta, Nicolas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poirel, Odile</au><au>Mamer, Lauren E.</au><au>Herman, Melissa A.</au><au>Arnulf-Kempcke, Marie</au><au>Kervern, Myriam</au><au>Potier, Brigitte</au><au>Miot, Stephanie</au><au>Wang, Jing</au><au>Favre-Besse, Franck-Cyril</au><au>Brabet, Isabelle</au><au>Laras, Younès</au><au>Bertrand, Hugues-Olivier</au><au>Acher, Francine</au><au>Pin, Jean-Philippe</au><au>Puel, Jean-Luc</au><au>Giros, Bruno</au><au>Epelbaum, Jacques</au><au>Rosenmund, Christian</au><au>Dutar, Patrick</au><au>Daumas, Stephanie</au><au>El Mestikawy, Salah</au><au>Pietrancosta, Nicolas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LSP5-2157 a new inhibitor of vesicular glutamate transporters</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>164</volume><spage>107902</spage><epage>107902</epage><pages>107902-107902</pages><artnum>107902</artnum><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Vesicular glutamate transporters (VGLUT1-3) mediate the uptake of glutamate into synaptic vesicles. VGLUTs are pivotal actors of excitatory transmission and of almost all brain functions. Their implication in various pathologies has been clearly documented. Despite their functional importance, the pharmacology of VGLUTs is limited to a few dyes such as Trypan Blue, Rose Bengal or Brilliant Yellow type. Here, we report the design and evaluation of new potent analogs based on Trypan Blue scaffold. Our best compound, named LSP5-2157, has an EC50 of 50 nM on glutamate vesicular uptake. Using a 3D homology model of VGLUT1 and docking experiments, we determined its putative binding subdomains within vesicular glutamate transporters and validated the structural requirement for VGLUT inhibition. To better estimate the specificity and potency of LSP5-2157, we also investigated its ability to block glutamatergic transmission in autaptic hippocampal cells. Neither glutamate receptors nor GABAergic transmission or transmission machinery were affected by LSP5-2157. Low doses of compound reversibly reduce glutamatergic neurotransmission in hippocampal autpases. LSP5-2157 had a low and depressing effect on synaptic efficacy in hippocampal slice. Furthermore, LSP5-2157 had no effect on NMDA-R- mediated fEPSP but reduce synaptic plasticity induced by 3 trains of 100 Hz. Finally, LSP5-2157 had the capacity to inhibit VGLUT3-dependent auditory synaptic transmission in the guinea pig cochlea. In this model, it abolished the compound action potential of auditory nerve at high concentration showing the limited permeation of LSP5-2157 in an in-vivo model. In summary, the new ligand LSP5-2157, has a high affinity and specificity for VGLUTs and shows some permeability in isolated neuron, tissue preparations or in vivo in the auditory system. These findings broaden the field of VGLUTs inhibitors and open the way to their use to assess glutamatergic functions in vitro and in vivo.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31811873</pmid><doi>10.1016/j.neuropharm.2019.107902</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5876-9822</orcidid><orcidid>https://orcid.org/0000-0002-9934-7818</orcidid><orcidid>https://orcid.org/0000-0002-6253-0002</orcidid><orcidid>https://orcid.org/0000-0002-8170-1196</orcidid><orcidid>https://orcid.org/0000-0002-7234-9987</orcidid><orcidid>https://orcid.org/0000-0002-5413-4181</orcidid><orcidid>https://orcid.org/0000-0002-9235-7298</orcidid><orcidid>https://orcid.org/0000-0001-7048-7617</orcidid><orcidid>https://orcid.org/0000-0002-1423-345X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-3908
ispartof Neuropharmacology, 2020-03, Vol.164, p.107902-107902, Article 107902
issn 0028-3908
1873-7064
language eng
recordid cdi_hal_primary_oai_HAL_hal_03043497v1
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Action Potentials - drug effects
Animals
Cochlea - drug effects
Cochlear Nerve - drug effects
Excitatory Postsynaptic Potentials - drug effects
Glutamatergic transmission modulation
Guinea Pigs
Hippocampus - cytology
Hippocampus - drug effects
Life Sciences
Mice
Mice, Inbred C57BL
Models, Molecular
Neurobiology
Neurons - drug effects
Neurons and Cognition
Neuropharmacology
Synapses - drug effects
Synaptic Transmission - drug effects
Vesicular Glutamate Transport Proteins - antagonists & inhibitors
Vesicular Glutamate Transport Proteins - metabolism
Vesicular glutamate transporters (VGLUTs)
title LSP5-2157 a new inhibitor of vesicular glutamate transporters
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A13%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LSP5-2157%20a%20new%20inhibitor%20of%20vesicular%20glutamate%20transporters&rft.jtitle=Neuropharmacology&rft.au=Poirel,%20Odile&rft.date=2020-03-01&rft.volume=164&rft.spage=107902&rft.epage=107902&rft.pages=107902-107902&rft.artnum=107902&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2019.107902&rft_dat=%3Cproquest_hal_p%3E2322742540%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2322742540&rft_id=info:pmid/31811873&rft_els_id=S0028390819304733&rfr_iscdi=true